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INTRODUCTION 
In July 1979, in accordance with the Joint Commission on Accredita-
tion of Hospitals (JCAH) standards, the Pharmacy and Therapeutics 
Committee approved a policy for reporting adverse drug reactions (ADRs) 
occurring within the 370-bed University of Utah Hospital. This policy 
was intended "to provide a mechanism to accurately and completely 
report adverse drug reactions which are suspected within the hospital". 
It required the health care provider initially suspecting the adverse 
drug reaction to complete an Adverse Drug Reaction Experience Report 
Form (Food and Drug Administration Form #1639). These report forms 
were to be available at each inpatient unit and outpatient clinic. The 
completed form was to be left in the pharmacy medication order box or 
taken directly to the pharmacy. In turn, all pharmacy personnel were 
to immediately forward the Adverse Drug Experience Report to the Drug 
Information Center. A follow-up was then conducted on each of these 
reports. The results were to be sent to the Food and Drug Administra-
tion and a copy kept on file within the Drug Information Center. 
The result of this policy has been the submission of seven reports 
between July 1979 and December 1983, three by physicians and four 
completed by pharmacists. For the two years prior to July of 1979, 
there were three adverse drug reaction reports submitted, all from 
pharmacy personnel. This results in an overall report rate of ten 
suspected adverse drug reactions in a six-and-one-half year period. 
During this time there were 76,090 admissions to the University Hospital, 
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which results in an apparent adverse drug reaction incidence of 0.013 
per 100 admissions. 
Several inpatient adverse drug reaction studies have demonstrated 
much higher incidences of adverse drug reactions. For example Wang et 
al^ utilized an active means of surveillance and review that identified 
128 adverse drug reactions among 8291 patients reviewed over a 12 month 
period, resulting in an incidence of 1.54%. Other surveillance studies 
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using active methods of review including those of Smidt et al, Ogilvie 
3 4 5 et al, Hurwitz et al, and Seidl et al, revealed adverse drug reaction 
incidences of 3%, 26.4%, 11.12%, and 25.8%, respectively. Further, a 
voluntary system of adverse drug reaction reporting conducted by 
Schimmel^ revealed an incidence of 9.5%. 
Most of these studies used active methods of review and reporting 
of adverse drug reactions instead of voluntary methods. Such active 
methods of review and reporting involve the use of a trained profession-
al or paraprofessional to conduct chart reviews and personal interviews 
with physicians, nurses, and patients in an attempt to identify the 
occurrence of adverse drug reactions. The advantages of the active 
reporting methods over voluntary methods are greater recognition, 
reporting and follow-up of adverse drug reactions. However, increased 
personnel time, cost and a lack of widespread coverage of patient 
populations, therapies, and pathology constitute major drawbacks to the 
use of active methods of monitoring and reporting. 
Despite the increased rate of reporting and decreased need for 
follow-up with active reporting, voluntary methods can potentially 
monitor greater numbers of patients at a lesser cost. Still, the 
voluntary systems are dependent on the suspicion or recognition of 
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potential adverse drug reactions by health care personnel and their 
awareness of the need for reporting. 
A comparison of published incidence data and the incidence of 
adverse drug reactions reported with University Hospital leads to the 
logical conclusion that many adverse drug reactions are unrecognized or 
unreported. This lack of spontaneous reporting and/or recognition is 
disconcerting, as adverse drug reactions increase morbidity, mortality, 
hospital admissions,^ length of stay,^ and cost per hospitalization.^ 
It is also not unreasonable to infer that adverse drug reactions could 
be implicated in the additional prescribing of medications; with 
physicians attempting to treat the unrecognized adverse drug reaction 
with additional drug therapy. 
This lack of spontaneous reporting may be attributed to various 
reasons, including: 1) the reactions may not be recognized as being 
drug-induced, 2) an adverse drug reaction considered unimportant may 
not be reported, 3) reporting an adverse drug reaction may be perceived 
as an admission of poor medical practice or increased liability, 4) 
personnel may have a poor understanding of the reporting form and/or 
method, 5) they may be apathetic or indifferent to the need for 
reporting, 6) the "nuisance factor" of filling out and filing an 
adverse drug reaction report. 
It is this last reason for nonreporting, the nuisance factor, 
which raises the question of whether a more obvious and readily access-
ible means of voluntary reporting would provide an increased incidence 
of reporting. Indeed, to evaluate the influence that complexity of the 
reporting form has on compliance, the Food and Drug Administration 
developed a shortened version of their Adverse Drug Reaction Experience 
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Reporting Form (form #1639a). However, to date there have been no 
published data verifying or suggesting a difference in reporting 
incidence relative to the length of the reporting form. 
It was for these reasons (i.e., the question of accessibility and 
visibility of the forms, complexity of forms, and the low incidence of 
reported adverse drug reactions at University Hospital) that the need 
was realized to identify a voluntary reporting system which could and 
would be adhered to by the medical staff. This system needed to serve 
as a marker to raise suspicion about potential adverse drug reactions. 
These needs were recognized through the concern and desire for a system 
that would facilitate the proper monitoring of adverse reactions to 
drugs. Furthermore, recommendations made to the University of Utah 
Hospital Pharmacy at a recent inspection by the JCAH stated "the 
University of Utah Hospital is in need of a method assuring better 
compliance with the adverse drug reaction reporting system". 
Thus, the objectives of this study were 1) to assess the general 
compliance rate of a more accessible reporting system, 2) to determine 
whether the format of a short form versus a long form is more acceptable 
to physicians, 3) to compare the incidence of reported adverse drug 
reactions using a reporting form to the incidence of adverse drug 
reactions reported in the medical record, and 4) to compare the inci-
dence of adverse drug reactions with the new system versus the incidence 
for the prior system. 
POPULATION AND METHODS 
The study population consisted of all physicians caring for 
inpatients on 4 North and 5 North nursing units of the medicine service 
during the defined eight week study period. 
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This descriptive pilot study examined the reporting of suspected 
adverse drug reactions. (NOTE: Suspected adverse drug reactions were 
emphasized in ar.y communications with physicians to eliminate the need 
for dechallenges, rechallenges, temporal and causal relationships, and 
the potential for interpretation differences.) Furthermore, the 
definition of an adverse drug reaction used in this study and communi-
g 
cated to physicians was from Kramer et al. The definition states "an 
adverse drug reaction is an undesirable clinical manifestation that is 
consequent to and caused by the administration of a particular drug. 
The clinical manifestation may be an abnormal sign, symptom, or labora-
tory test, or it may be a cluster of abnormal signs, symptoms, and 
tests." 
During the defined eight week study period all patients admitted 
to the 4 North and 5 North nursing units had one of two styles of 
reporting forms randomly placed in the front of their charts by the 
unit clerk (Appendices 1 & 2). Each form was labeled "Report For 
Suspected Adverse Drug Reaction(s)", and included instructions for the 
unit clerk explaining proper distribution and collection. Further 
instructions to physicians included the fact that the forms were not 
intended as permanent additions to the patients' charts, and would be 
removed upon their discharge. These forms were also distributed to all 
charts of existing inpatients on the two units. The forms were intended 
to be distributed by the unit clerks, who received a stack of forms in 
which the long style and short style forms had been alternately placed. 
At the beginning of the study each unit clerk received a memorandum and 
a personal briefing by the investigator explaining the appropriate 
distribution and collection of the forms. Furthermore, weekly checks 
of the inpatient charts were made by the investigator to assess unit 
clerk compliance, as well as to place forms in those charts lacking 
them. Also, in order to assure optimal collection of forms from the 
charts of discharged patients, the medical records specialist serving 
the two study units was asked to collect any study forms that were not 
previously removed from the patient charts. 
The forms were to be collected upon suspicion of an adverse drug 
reaction, or upon termination of the patients' inpatient stay. If 
there were no suspected adverse drug reactions, the physician was to 
check the box labeled "no suspected adverse drug reaction". However, 
if there was a suspected reaction, the form was to be filled out 
completely. 
The housestaff physicians were notified in writing of the implemen-
tation of the reporting system, their proposed role in completing the 
forms, and that various form styles would be tried initially. Memoranda 
were distributed to all housestaff physicians prior to, and at the 
midpoint of the study period (Appendices 3 & 4). The memorandum 
distributed at the midpoint of the study also included an update of any 
reported adverse drug reactions during the first half of the study. 
The final step in this study involved a chart review conducted by 
the investigator. Fifty charts were randomly selected from those of 
patients discharged from the study units during the study period. This 
review focused on all progress notes and discharge summaries written 
regarding the specific hospital admission for which a reporting form 
had been distributed and collected. This review was conducted with the 
intention of detecting any mention of a suspected adverse drug reaction, 
which may have taken place during the patient's hospitalization. Also, 
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any suspected adverse drug reaction that may have lead to the current 
hospitalization was noted. 
The data analysis for this study consisted of descriptive informa-
tion involving the number of forms distributed and collected, and the 
number of adverse drug reactions reported in charts and on forms (Table 
1). The calculations performed on the data included: 
Physician = Total # of forms completed (+ or -) for ADR X 100 
Compliance Rate Total # of forms distributed and collected 
Form versus = % of suspected ADR reported on forms 
Chart Reporting % of suspected ADR reported in charts 
Comparison of = Incidence of reported ADR in current study 
Reporting Systems Prior incidence of ADR for University Hospital 
RESULTS 
During the eight week study period, equal numbers of short and 
long style forms were distributed to the study units. During the 
study, 259 forms were distributed to patient charts and collected upon 
their discharge. Eighty-eight of these forms were recovered by the 
medical records specialist. Within this same period there were 488 
discharges, giving a compliance rate for unit clerks distributing and 
collecting forms of 35% (259 - 88 forms/488 potential). 
The number of suspected adverse drug reactions reported during 
this study was two. Neither of these positive reports for adverse drug 
reactions were appropriately completed, with the majority of elements 
on each form remaining unanswered. There was one form checked as 
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having "no suspected adverse drug reaction", therefore 256 forms 
remained blank. This number of adverse drug reactions reported in 
conjunction with the total number of forms distributed to charts and 
collected, was used to determine the reported incidence of suspected 
reactions. This incidence of reported suspected adverse drug reactions 
was 0.77%. In comparison, the prestudy incidence was 0.013%. ,Of the 
50 charts reviewed for the presence of suspected adverse drug reactions, 
22 had one or more suspected reactions reported. Thus, the incidence 
of suspected adverse drug reactions in the charts for this representa-
tive sample was 44%. Furthermore, the one form which indicated "no 
suspected adverse drug reaction" was from a chart in which a suspected 
adverse drug reaction was noted. 
The study objective of comparing reporting incidence with the 
short form style versus the long form style was unattainable, as only 
one suspected adverse drug reaction was reported on each form type. 
The physician compliance rate for the number of forms completed (+ or 
-) for adverse drug reactions was 1.2%. The degree of reporting on 
forms versus charts was 0.0175. 
DISCUSSION 
There were several inherent problems with this study. The eight 
week study period was much shorter than most of the published studies."^  
Because of this shorter period, the sample was too small to allow 
statistical analysis. The unit clerk compliance for distributing and 
collecting the reporting forms was very poor. This occurred despite 
the prior authorization of the Pharmacy and Therapeutics Committee, 
Nursing Administration, Medical Records Director, and Floor Charge 
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Nurses for the units utilized in the study. There were several remind-
ers given to unit clerks by the investigator. 
The incidence of suspected adverse drug reactions reported in this 
study was much greater than the incidence prior to the study, (0.77% 
versus 0.013%). It is important to note that the 0.77% was calculated 
by dividing the number of suspected adverse drug reaction reports by 
the number of report forms distributed to patient charts and collected, 
whereas, 0.013% was arrived at by dividing the number of reports by 
total patient admissions. This was done because it was felt the new 
reporting system was designed for high visibility and accessibility, 
and therefore could only be assessed in relation to actual exposure to 
the reporting forms. Despite the higher reporting incidence, the 
number of responses to the forms (+ or -) for the presence of suspected 
adverse drug reactions was very low, with only three responses out of 
259 possible. This still raises the questions of whether the physicians 
felt the adverse drug reactions were unimportant, whether they increased 
professional liability, or whether apathy or the "nuisance factor" was 
the cause of the low incidence of reporting. However, in reviewing the 
patient charts it became evident there are a great many suspected 
adverse drug reactions that are noted yet never reported on the forms. 
This suggests physicians do find adverse drug reactions important and 
are not concerned with the liability issue. It may be that the physi-
cians felt unfamiliar with the reporting form and new system. This 
appears to be unlikely in view of the two memoranda explaining the 
forms and systems, and the constant high visibility and accessibility 
of the forms. 
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An interesting addition to the present study would have been the 
inclusion of a questionnaire to the housestaff asking for a preferred 
method of adverse drug reaction reporting, as well as their views on 
the recently studied system. Other points of interest which could not 
have been determined in this study due to time constraints are whether 
the reporting incidence increases or decreases with familiarization 
with the process, if the presence of a more visible adverse drug 
reaction reporting system would heighten awareness and suspicion, and 
whether periodic bulletins and inservices to the medical staff on the 
monitoring of drug therapy would result in increased reporting. 
CONCLUSIONS AND RECOMMENDATIONS 
The physician compliance rate for this highly visible and access-
ible system was very poor. The objective of determining the acceptabil-
ity of a reporting form with a long format versus a short format was 
unattainable. The study also reveals that physicians report suspected 
adverse drug reactions much more readily in patient charts than on 
reporting forms. Also, the apparent incidence of adverse drug reactions 
reported with the new system was much higher than the prior system. 
The low compliance rate for this system suggests a lack of coopera-
tion or a misunderstanding of the new reporting system. The unattain-
able objective analyzing form length failed because of the low incidence 
of reporting and the short period over which the pilot study took 
place. This study suggests that the reasons for the low incidence of 
adverse drug reaction reporting on forms are the nuisance involved, 
indifference, or the misunderstanding for the need of reporting in both 
the chart and form. 
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Because of these proposed reasons for nonreporting, and the 
increased reporting incidence of the new system over the previous, it 
should be quite useful to conduct another pilot study which utilizes 
physicians in designing a more acceptable form. This involvement 
should help reduce problems of misunderstanding and indifference. 
Further, the pilot study should include a questionnaire directed to 
physicians' feelings regarding the reporting form and system. In light 
of the higher incidence of spontaneous adverse drug reaction reporting 
in the medical record, perhaps an active surveillance program involving 












Number of forms distributed to floors 
Long style 
Short style 
Number of forms distributed to charts and collected 
Number of forms remaining in charts at termination 1 8 
of study 
Number of unused forms returned to investigator 33 27 
Number of forms unaccounted for 
Number of patient admissions during study period 212 221 
Number of patient discharges during study period 258 230 
Number of suspected ADR's^ - -
Number of forms with responses (+ or -) for ADR's - -
Number of charts reviewed 
Number of charts having one or more suspected ADR's - -
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ATTENTION: Unit Clerk, please place form in patient's chart at time 
of admission (with patient Hospital # on it) and remove 
form at time of discharge. 
Report for Suspected Adverse Drug Reaction(s) 
1) Patient Hospital I.D. number? 
2) Did this patient experience a suspected ADR? 
No Suspected ADR No further questions need be answered. 
If yes — please complete form accordingly. 
3) What was the date of reaction onset? 
A) What was the suspected reaction? 
5) What is/are the responsible drug(s)? 
6) Did this reaction alter therapy? If so, how? 
7) Comments (including other suspected ADRs). 
This form is not part of patient's permanent medical record and will be 
removed from chart at time of discharge. 
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ATTENTION: Unit Clerk, please place form in patient's chart at time 
of admission (with patient Hospital # on it) and remove 
form at time of discharge. 
Report for Suspected Adverse Drug Reaction(s) 
1) Patient Hospital I.D. Number: 
2) Did this patient experience a suspected ADR? 
No suspected ADR No further questions need be answered. 
If yes — Please complete form accordingly. 
3) What was the date of reaction onset? 
4) What was the suspected reaction? 
5) What is/are the responsible drug(s)? 
6) What was the reason for use of the drug? 
7) Route? 
8) Daily dose? 
9) Date of first administration? 
10) Were other drugs taken concomitantly? If so, which? 
11) Comments (including other suspected ADRs) 
12) Did this reaction alter therapy? If so, how? 
13) Physician's name: 
This form is not part of patient's permanent medical record and will be 
removed from chart at time of discharge. 
e xioNajjv 
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M E M O R A N D U M 
TO: Housestaff Physicians 
FROM: Pharmacy and Therapeutics Committee 
DATE: March 5, 1984 
SUBJECT: Adverse Drug Reaction (ADR) Reports 
Within the next week all charts for inpatients shall contain an addition-
al form. This form will be part of an Adverse Drug Reaction Reporting 
System for the University of Utah Hospital. It would be most helpful 
if any physician caring for an inpatient would fill out the questionnaire 
at the time of patient's discharge, or earlier if there is suspicion 
that an ADR is occurring or has occurred. If it was felt that the 
patient did not experience an ADR, then please check the box indicating 
"No Suspected ADR" and no further questions need be answered. However, 
if it is felt that the patient may have experienced a suspected ADR**, 
then please complete the form accordingly. 
These forms are being implemented as fulfillment of JCAH requirements 
(which were reiterated to the Pharmacy and Therapeutics Committee at 
the recent site visit). In order that we may all benefit more directly 
from these forms, a memo will be distributed to you every two weeks to 
report on the responses to the system (i.e., number and type of ADRs 
reported). Initially, forms will only be distributed to 5N and 4N 
medical floors. 
These forms are NOT intended to be part of the patient's permanent 
medical record and will be removed from the chart at the time of 
patient's discharge. They will then be examined by the Pharmacy and 
Therapeutics Committee. Various forms will be tried initially, there-
fore, please fill out a form for every patient upon his/her discharge. 
Your compliance with this system will be greatly appreciated and will 
benefit us all. 
For further information please contact the Drug Information Center, 
Ext. 2073. 
**Adverse Drug Reaction (ADR) — An ADR is an undesirable clinical 
manifestation that is consequent to and caused by the administration of 
a particular drug. The clinical manifestation may be an abnormal sign, 
symptom, or laboratory test, or it may be a cluster of abnormal signs, 
symptoms, and tests. 
These reports need not be for verified ADRs, but rather the suspicion 
that one may have occurred. 
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M E M O R A N D U M 
TO: Housestaff Physicians 
FROM: Pharmacy and Therapeutics 
DATE: April 23, 1984 
SUBJECT: Adverse Drug Reaction (ADR) Reports 
During the past 5 weeks Adverse Drug Reaction Reporting forms have 
been distributed to all inpatients on 4 North and 5 North. These forms 
are part of an Adverse Drug Reaction Reporting System for the University 
of Utah Hospital. They were implemented as fulfillment of JCAH require-
ments and the need for greater awareness of ADR's. 
It is most helpful if any physicians caring for an inpatient would 
fill out the questionnaire at the time of patient's discharge, or 
earlier if there is suspicion that an ADR is occurring or has occurred. 
If it was felt that the patient did not experience an ADR, then please 
place a check-mark in the spot indicating "No Suspected ADR" and no 
further questions need be answered. However, for suspected ADR's please 
complete the form accordingly. 
To date only 1 ADR has been reported; this involved the local 
infiltration of Conray 43 (IV contrast dye) into soft tissue. The 
subsequent reaction resulted in local sloughing of skin. 
These forms are NOT intended to be part of the patient's permanent 
record and will be removed from the chart at the time of patient's 
discharge. They will then be examined by the Pharmacy and Therapeutics 
Committee. 
For further information, please contact the Drug Information 
Center, extension 2073. 
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